How would you approach cytopenias 5 weeks after initial dosing in a young patient with MDS treated with Azacitadine as a bridge to transplant?
E.g. would you dose-reduce or continue at same dose?
Baseline ANC was in the normal range
1 Answer
Mednet MemberInvited Expert
Medical Oncology · University of Maryland Cancer Center
Answered on
Bridging with HMA to transplant in MDS patients is a common practice although it did not show improved outcomes. You will definitely have to r/o other potential causes of pancytopenia (i.e., infections, etc). I would repeat a BM A/Bx to make sure that blasts are not increasing (< 20% and preferably ...
Join for free or sign in to see the full answer